Company: ZLAB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038548
Chunk: 8

Company: Zai Lab Ltd
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 2
Chunk 8
---
.3 million, respectively, which are related to promotional activities in mainland China.

Research and Development Expenses 

The following table presents the components of our research and development expenses ($ in thousands):

Three Months Ended June 30,ChangeSix Months Ended June 30,Change20252024$%20252024$%Personnel compensation and related costs22,447 31,209 (8,762)(28)%46,527 59,217 (12,690)(21)%Licensing fees— — — NM19,997 — 19,997 NMCROs/CMOs/Investigators expenses19,935 24,305 (4,370)(18)%29,765 44,209 (14,444)(33)%Other costs8,232 6,111 2,121 35 %15,054 12,844 2,210 17 %Total50,614 61,625 (11,011)(18)%111,343 116,270 (4,927)(4)%

NM - Not Meaningful

Research and development expenses decreased by $11.0 million and $4.9 million in the three and six months ended June 30, 2025, respectively, primarily due to: 

•a decrease of $8.8 million and $12.7 million, respectively, in personnel compensation and related costs primarily driven by our resource prioritization and efficiency efforts,

•a decrease of $4.4 million and $14.4 million, respectively, in CROs/CMOs/Investigators expenses related to ongoing clinical trials; partially offset by, 

•an increase of nil and $20.0 million, respectively, in licensing fees for our license and collaboration agreements.

23

The following table presents our research and development expenses by program ($ in thousands):

Three Months Ended June 30,ChangeSix Months Ended June 30,Change20252024$%20252024$%Clinical programs16,967 21,348 (4,381)(21)%45,059 40,136 4,923 12 %Pre-Clinical programs5,069 3,139 1,930 61 %8,383 5,188 3,195 62 %Unallocated research and development expenses28,578 37,138 (8,560)(23)%57,901 70,946 (13,045)(18)%